Ndje Amandine, Broadway-Duren Jacqueline B
The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Adv Pract Oncol. 2022 Nov;13(8):822-826. doi: 10.6004/jadpro.2022.13.8.9. Epub 2022 Nov 1.
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare cancer with primary sites in the skin and bone marrow and secondary sites in the lymph nodes, spleen, and central nervous system. First described in the 1990s, these cells express a CD123 antigen hinting at a plasmacytoid dendritic cell origin. A CD123-directed cytotoxin called SL-401 was approved by the US Food and Drug Administration and the European Medicines Agency. During BPDCN treatment, a life-threatening syndrome can occur, but early awareness leads to positive patient outcomes.
母细胞性浆细胞样树突状细胞肿瘤（BPDCN）是一种罕见的癌症，原发部位在皮肤和骨髓，继发部位在淋巴结、脾脏和中枢神经系统。20世纪90年代首次被描述，这些细胞表达CD123抗原，提示其起源于浆细胞样树突状细胞。一种名为SL-401的靶向CD123的细胞毒素已获美国食品药品监督管理局和欧洲药品管理局批准。在BPDCN治疗期间，可能会出现危及生命的综合征，但早期识别可带来积极的患者预后。
